PARIS – A team of medical researchers and engineers from the Gustave Roussy Institute, in Villejuif, France, and Paris-Sud University recently developed an artificial intelligence system called Resolved2, designed to assess prospective cancer drugs. As Loïc Verlingue, lead cancer specialist on the data science team at the Gustave Roussy Institute, explained to BioWorld MedTech, “this AI is intended to predict efficiently whether a cancer treatment molecule will achieve authorization or not within six years of pharmacological data and phase I clinical trials.”
DUBLIN – The European Medicines Agency’s Committee for Medicinal Products for Human Use closed out its year’s work with positive opinions on two applications, Novartis AG’s Beovu (brolucizumab) in wet age-related macular degeneration and Merck & Co. Inc.’s Recarbrio for treating gram negative infections in adults.
LONDON – Over the next decade pharmacovigilance will move on from a sole focus on adverse drug reactions (ADRs) to encompass monitoring of the in-market efficacy of medicines, according to Guido Rasi, executive director of EMA.
LONDON – Dutch startup Enzyre BV is teaming up with Takeda Pharmaceutical Co. Ltd. to complete development of a home diagnostic device that aims to make it as easy for hemophiliacs to self-test their coagulation status as it is for diabetics to monitor their blood sugar levels.
LONDON – Scientists in the U.K. are claiming a world first, after successfully reproducing the electrophysiology of biological neurons in silicon chips. It is said that artificial neurons respond to non-linear physiological feedback in real time, in exactly the same way as their biological counterparts.
LONDON – Scientists in the U.K. are claiming a world first, after successfully reproducing the electrophysiology of biological neurons in silicon chips. It is said that artificial neurons respond to non-linear physiological feedback in real time, in exactly the same way as their biological counterparts. Crucially, in terms of their use in medical implants, the analogue chips have a power consumption 109 times lower than equivalent digital microprocessors, which other attempts to make synthetic neurons have used.
PARIS – Grapheal SAS, of Grenoble, France, is developing a new generation of dressings integrating an embedded electronic biosensor. The Grapheal device consists of monolayer graphene on a polymer layer 0.3 nanometers thick. “This noninvasive embedded device collects data from the wound. The wireless e-health wound monitoring system, or smart patch, remotely reports the status of chronic wounds to the care team,” Vincent Bouchiat, co-founder and CEO at Grapheal, told BioWorld MedTech.
LONDON – Advanced Oncotherapy plc is starting verification and validation of the world’s first linear proton beam accelerator system, which is assembled and ready for testing at the Daresbury particle physics laboratory in Cheshire, U.K.
HONG KONG – Celltrion Healthcare Co. Ltd., a South Korean biopharmaceutical corporation, won European Union (EU) marketing approval for Remsima SC for the treatment of rheumatoid arthritis (RA), as a subcutaneous version of Celltrion’s infliximab biosimilar, CT-P13.
LONDON - The number of biotech startups in the U.K. increased by almost 50% between 2014 and 2018, compared to 2012 – 2016, according to the latest data from the consultancy Biocity, which has been tracking the sector since 2005.
RSS
